Prevention of Doxorubicin-Induced Hair Loss with Scalp Hypothermia
- 27 December 1979
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 301 (26) , 1427-1429
- https://doi.org/10.1056/nejm197912273012605
Abstract
THE psychological impact of chemotherapy-induced alopecia represents one of the more devastating side effects of cancer chemotherapy and, in some instances, leads patients to refuse potentially curative chemotherapy. The problem of alopecia is severe when patients are treated with the anthracycline antibiotic, doxorubicin (adriamycin), which is beneficial in many types of cancer (e.g., breast, lung, ovary, sarcomas, lymphomas, and leukemias).1 2 3 4 5 6 In 1973, Luce and his co-workers achieved good protection against doxorubicin-induced alopecia in 12 of 15 patients by means of regional direction of chilled air to the scalp.7 More recently, Edelstyn's group used cryogel packs held on the scalp with . . .Keywords
This publication has 8 references indexed in Scilit:
- Physiologically based pharmacokinetic models for anticancer drugsCancer Chemotherapy and Pharmacology, 1979
- Thermometry considerations in localized hyperthermiaMedical Physics, 1978
- DOXORUBICIN-INDUCED HAIR LOSS AND POSSIBLE MODIFICATION BY SCALP COOLINGThe Lancet, 1977
- The value of adriamycin in overcoming resistance to methotrexate in tissue culturePublished by Elsevier ,1976
- Cutaneous Complications of Cancer ChemotherapyPostgraduate Medicine, 1975
- Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancerCancer, 1975
- AdriamycinAnnals of Internal Medicine, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958